Brian B. Hasinoff

6.3k total citations
182 papers, 5.3k citations indexed

About

Brian B. Hasinoff is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Brian B. Hasinoff has authored 182 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Molecular Biology, 60 papers in Cardiology and Cardiovascular Medicine and 43 papers in Oncology. Recurrent topics in Brian B. Hasinoff's work include Chemotherapy-induced cardiotoxicity and mitigation (57 papers), Cancer therapeutics and mechanisms (47 papers) and Electron Spin Resonance Studies (28 papers). Brian B. Hasinoff is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (57 papers), Cancer therapeutics and mechanisms (47 papers) and Electron Spin Resonance Studies (28 papers). Brian B. Hasinoff collaborates with scholars based in Canada, United States and United Kingdom. Brian B. Hasinoff's co-authors include Daywin Patel, Xing Wu, Jack C. Yalowich, Eugene H. Herman, Jean Rivoal, Patricia Schroeder, Krisztina L. Malisza, Joan L. Buss, H. Brian Dunford and Kimberley A. O’Hara and has published in prestigious journals such as Annals of Internal Medicine, Biochemistry and Cancer Research.

In The Last Decade

Brian B. Hasinoff

180 papers receiving 5.2k citations

Peers

Countries citing papers authored by Brian B. Hasinoff

Since Specialization

Citations

This map shows the geographic impact of Brian B. Hasinoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian B. Hasinoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian B. Hasinoff more than expected).

Fields of papers citing papers by Brian B. Hasinoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian B. Hasinoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian B. Hasinoff. The network helps show where Brian B. Hasinoff may publish in the future.

Co-authorship network of co-authors of Brian B. Hasinoff

This figure shows the co-authorship network connecting the top 25 collaborators of Brian B. Hasinoff. A scholar is included among the top collaborators of Brian B. Hasinoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian B. Hasinoff. Brian B. Hasinoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane 2019 ·Cardiovascular Toxicology ·Brian B. Hasinoff, Daywin Patel, Xing Wu	29
2	Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome 2018 ·Archives of Biochemistry and Biophysics ·Brian B. Hasinoff	10
3	Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs 2015 ·Bioorganic & Medicinal Chemistry ·Arun A. Yadav, (unknown), Xing Wu, Daywin Patel, Jack C. Yalowich, Brian B. Hasinoff	7
4	Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents 2011 ·Bioorganic & Medicinal Chemistry ·Rui Zhang, Xing Wu, Jack C. Yalowich, Brian B. Hasinoff	25
5	Kinamycin F downregulates cyclin D3 in human leukemia K562 cells 2010 ·Chemico-Biological Interactions ·Kimberley A. O’Hara, Gary I. Dmitrienko, Brian B. Hasinoff	17
6	The Dihydroorotase Inhibitor 5-Aminoorotic Acid Inhibits the Metabolism in the Rat of the Cardioprotective Drug Dexrazoxane and Its One-Ring Open Metabolites 2008 ·Drug Metabolism and Disposition ·Patricia Schroeder, Daywin Patel, Brian B. Hasinoff	14
7	The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent 2007 ·Cardiovascular Toxicology ·Brian B. Hasinoff, Daywin Patel, Xing Wu	25
8	Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress 2003 ·The Plant Journal ·(unknown), Brian B. Hasinoff, Abir U. Igamberdiev, (unknown), Jean Rivoal, Robert D. Hill	232
9	Dexrazoxane (ICRF-187) Protects Cardiac Myocytes Against Hypoxia-Reoxygenation Damage 2002 ·Cardiovascular Toxicology ·Brian B. Hasinoff	34
10	Chemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines 1998 ·Current Medicinal Chemistry ·Brian B. Hasinoff, K. Hellmann, Erik Herman, V J Ferrans	131
11	Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II 1997 ·Biochemical Pharmacology ·Brian B. Hasinoff, Theodore I. Kuschak, Andrew M. Creighton, Cheryl L. Fattman, William P. Allan, (unknown), Jack C. Yalowich	40
12	Antioxidants and Dipyridamole Inhibit HIV-1 gp120-Induced Free Radical-Based Oxidative Damage to Human Monocytoid Cells 1997 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·(unknown), Avindra Nath, Brian B. Hasinoff, Jonathan D. Geiger	40
13	Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells 1996 ·Biochemical Pharmacology ·Cheryl L. Fattman, William P. Allan, Brian B. Hasinoff, Jack C. Yalowich	38
14	A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane) 1995 ·Biochemical Pharmacology ·Brian B. Hasinoff, Theodore I. Kuschak, Jack C. Yalowich, Andrew M. Creighton	96
15	The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes 1993 ·Inflammation Research ·Joan L. Buss, Brian B. Hasinoff	58
16	The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925 1993 ·Inflammation Research ·Brian B. Hasinoff, Subbarao V. Kala	17
17	Ferrous Sulfate Reduces Thyroxine Efficacy in Patients with Hypothyroidism 1992 ·Annals of Internal Medicine ·Norman R.C. Campbell, Brian B. Hasinoff, (unknown), (unknown), (unknown)	146
18	The Adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper 1989 ·Xenobiotica ·Brian B. Hasinoff, (unknown), Peter J. O’Brien	15
19	Self-reduction of the iron(III)-doxorubicin complex 1989 ·Free Radical Biology and Medicine ·Brian B. Hasinoff	19
20	Adriamycin and its iron(III) and copper(II) complexes 1988 ·Biochemical Pharmacology ·Brian B. Hasinoff, (unknown)	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact